हिंदी में पढ़ें

Lupin

Stocks in Focus on August 28: Lakshmi Vilas Bank, Yes Bank to GHCL; here are the 5 Newsmakers of the Day

Stocks in Focus on August 28: Lakshmi Vilas Bank, Yes Bank to GHCL; here are the 5 Newsmakers of the Day

Wed, Aug 28, 2019

Certain stocks came in news post-market hours yesterday and can have an impact on the market when it reopens today.

Buy or Sell: Stock market experts speak on Bajaj Finance, Lupin and Hexaware stocks

Buy or Sell: Stock market experts speak on Bajaj Finance, Lupin and Hexaware stocks

Thu, Aug 08, 2019

Stock market experts are advising fresh buy in Bajaj Finance futures while they advise investors to avoid fresh buy in Lupin but one can hold the stock who have this stock in their portfolio. In Hexaware, one can buy the stocks for 4-5 per cent gains.

Lupin, M&M to Tata Steel - Which stocks should you buy?

Lupin, M&M to Tata Steel - Which stocks should you buy?

Thu, Aug 08, 2019

Edelweiss said that Lupin’s current valuation of 17.8x FY21E EPS – amid depressed earnings – offers an attractive entry point in its view.

TRENDING NOW

Stock market tip: Which shares should you invest in?

Stock market tip: Which shares should you invest in?

Fri, Jul 19, 2019

It is very difficult to decide on right stock picks when the market is in the negative territory. When the market is volatile, the investors need to tread very cautiously to gain from the trades. Here are Brokerage Edelweiss' report on these 5 prospective shares:

Lupin recalls over 12,000 cartons of birth control tablets from US market

Lupin recalls over 12,000 cartons of birth control tablets from US market

Sun, Apr 07, 2019

Lupin Pharmaceuticals Inc is recalling 12,464 cartons of the Fayosim (levonorgestrel and ethinyl estradiol) tablets USP, (0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg)

Rakesh Jhunjhunwala stock Lupin share price 2019 suffers big setback from experts now

Rakesh Jhunjhunwala stock Lupin share price 2019 suffers big setback from experts now

Wed, Mar 27, 2019

Rakesh Jhunjhunwala's holding in this stock is valued at above Rs 500 crore and is one of his favourites including Titan, NCC and Escorts.

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

Sun, Mar 17, 2019

Drug major Lupin Saturday said it has been cautioned by the US health regulator that its Somerset (New Jersey) facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

USFDA classifies Lupin's Somerset facility as 'Official Action Indicated'

Sat, Mar 16, 2019

The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed, the company added.

Experts give cautious call on this favorite Rakesh Jhunjhunwala stock - what you should know

Experts give cautious call on this favorite Rakesh Jhunjhunwala stock - what you should know

Thu, Mar 14, 2019

This favourite stock of Rakesh Jhunjhunwala has touched an intraday low of Rs 755 per piece in early opening trade.

Drug maker Lupin launches chronic angina treatment drug in the US

Drug maker Lupin launches chronic angina treatment drug in the US

Thu, Feb 28, 2019

"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added. Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.

Lupin recalls over 24,000 bottles of skin treatment drug from US

Lupin recalls over 24,000 bottles of skin treatment drug from US

Sun, Feb 03, 2019

According to USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Stock investment update: Ace investor Rakesh Jhunjhunwala removes money in this pharma-major - What should you do?

Stock investment update: Ace investor Rakesh Jhunjhunwala removes money in this pharma-major - What should you do?

Thu, Jan 17, 2019

Although, the ace investor has removed his money in Lupin on a marginal basis in Q3FY19, what is interesting to know is that this would be his second selling in this company.

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Mon, Dec 31, 2018

The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.

An intelligent and patient-friendly chatbot is trained to help patients with health-related concerns: Rajeev Sibal, Lupin

An intelligent and patient-friendly chatbot is trained to help patients with health-related concerns: Rajeev Sibal, Lupin

Tue, Dec 04, 2018

Indian pharmaceutical market has grown at 10-11% in the last 4-5 years and if you see the growth of Lupin, that it has grown by 16% from 2014 to 2018.

A third of pharmaceutical companies miss Q2 average estimate

A third of pharmaceutical companies miss Q2 average estimate

Tue, Nov 20, 2018

Almost one-third of the BSE 100 pharmaceutical companies have missed the average estimate in the quarter ended September 2018, pulled down by the lower sales and anti-trust litigation provision.

Lupin gets USFDA nod for generic contraceptive tablets

Lupin gets USFDA nod for generic contraceptive tablets

Wed, Aug 22, 2018

The company has received tentative approval for its Nudovra (Estradiol Valerate Tablets, 3 mg and 1 mg and Estradiol Valerate and Dienogest Tablets, 2 mg/2 mg and 2 mg/3 mg) tablets from the US Food and Drug Administration (FDA), Lupin said in a statement.

Lupin Q1 net profit dips 43 pc at Rs 203 cr

Lupin Q1 net profit dips 43 pc at Rs 203 cr

Wed, Aug 08, 2018

Drug firm Lupin today reported 43.37 per cent decline in its consolidated net profit at Rs 202.76 crore for the first quarter ended June 30, hit by drop in sales in the US and Japan

Lupin launches plaque psoriasis treatment spray in US market

Lupin launches plaque psoriasis treatment spray in US market

Fri, Jul 27, 2018

Drug major Lupin today announced the launch of Desoximetasone Topical Spray, used for treatment of plaque psoriasis, in the US market.

Rakesh Jhunjhunwala changes portfolio; These stocks got Big Bull's thumbs up; reason to buy?

Rakesh Jhunjhunwala changes portfolio; These stocks got Big Bull's thumbs up; reason to buy?

Fri, Jul 20, 2018

Rakesh Jhunjhunwala portfolio: Among 29 stocks where Rakesh Jhunjhunwala holds over 1 per cent stake, three saw his holdings go up. These include Lupin, NCC and Jaiprakash Associates.

Rakesh Jhunjhunwala buys 1 lakh shares of this pharma firm; stock soars

Rakesh Jhunjhunwala buys 1 lakh shares of this pharma firm; stock soars

Tue, Jul 17, 2018

Rakesh Jhunjhunwala owned 86,98,605 shares or 1.92 per cent stake in this firm at the end of the March quarter of financial year 2017-18. According to latest shareholding pattern available on the BSE, Jhunjhunwala increased his holding in the company by 1 lakh shares in the June quarter.

As rupee takes a record plunge, these 5 stocks can earn you hefty returns

As rupee takes a record plunge, these 5 stocks can earn you hefty returns

Thu, Jun 28, 2018

While rupee depreciation doesn't bode well for importers, it brings cheers for exporters who earn their revenues in rupees. We have compiled 5 stocks from export-oriented sectors such as information technology (IT) and pharma sectors for you to look at positively:

Maruti Suzuki, HDFC Bank among top stocks buzzing in Thursday's session

Maruti Suzuki, HDFC Bank among top stocks buzzing in Thursday's session

Thu, Jun 14, 2018

Lupin has announced that it has launched Tobramycin Inhalation Solution USP, in the US market. Lupin had already received USFDA approval for Tobramycin Inhalation from the USFDA.

Public sector banks spoil Q3 earnings party on D-Street

Public sector banks spoil Q3 earnings party on D-Street

Mon, Feb 19, 2018

Stock market investors who were expecting strong overall third-quarter earnings performance have a reason to feel disappointed.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x